Evidence map›Paper›PMID 11572321›Full record

ReviewEndocrine2001

Pulling strings below the surface: hormone receptor signaling through inhibition of protein tyrosine phosphatases.

X Espanel, S Wälchli, R P Gobert, M El Alama, M L Curchod, N Gullu-Isler, R Hooft van Huijsduijnen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 20 citations in OpenAlex.

  1. Decompartmentalizing target validation-thinking outside the pipeline boxes.Journal of molecular medicine (Berlin, Germany) · 2006
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

X EspanelSerono Pharmaceutical Research Institute, Geneva, Switzerland.
S Wälchli
R P Gobert
M El Alama
M L Curchod
N Gullu-Isler
R Hooft van Huijsduijnen
Merck (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hormones, cytokines, and related proteins (such as soluble hormone receptors) play an important role as therapeutic agents. Most hormone receptors signal through a mechanism that involves phosphorylation of the receptor's tyrosine residues. At any given moment, the receptor's phosphorylation state depends on the balance of kinase and phosphatase activities. Recent findings point to the exciting possibility that receptor signaling can be regulated by inhibition of protein tyrosine phosphatases (PTPs) that specifically hydrolyze receptor tyrosine-phosphates, or their immediate downstream effectors. This strategy has now been firmly validated for the insulin receptor and PTP1B; inhibiting PTP1B activity results in stimulation of the insulin receptor and signaling, even in the absence of insulin. This and similar findings suggest that PTP inhibitors have potential as hormone mimetics. In the present review, we outline this new paradigm for therapeutic regulation of the insulin receptor and discuss evidence that hints at other specific receptor-PTP pairs.

Indexed as

Signal TransductionAnimalsCarrier ProteinsEnzyme InhibitorsHumansPhosphorylationPhosphotyrosineProtein Tyrosine PhosphatasesReceptor, InsulinReceptors, Cell SurfaceReceptors, LeptinReceptors, SomatotropinCarrier ProteinsEnzyme InhibitorsPhosphotyrosineProtein Tyrosine PhosphatasesReceptor, InsulinReceptors, Cell SurfaceReceptors, LeptinReceptors, Somatotropin

Identifiers

PMID11572321
OpenAlexW1993317685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.